Jamieson Bondarenko buying at BriaCell Therapeutics (BCT)

Jamieson Bondarenko buying at BriaCell Therapeutics (T:BCT)

Jamieson Bondarenko, a Director and 10% Holder, acquired 1,271,000 Common Shares on a direct ownership basis at prices ranging from $0.085 to $0.090 between June 4th and 10th, 2019. This represents a $111,510 investment into the company's shares and an account share holdings change of 4.4%.

BriaCell Therapeutics is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.

BriaCell Therapeutics Corp. is a Canada-based immuno-oncology biotechnology company, which develops treatments for cancer. Its lead product candidate, Bria-IMT, is being tested in a clinical trial in combination with pembrolizumab in patients with advanced breast cancer. The Company also is developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer patients, and BriaDX, its companion diagnostic test. The Company's preclinical small molecule program consists of protein kinase C delta inhibitors for cancer and fibrotic diseases.